Alzheimers
Eisai presents latest findings for lecanemab at Alzheimer’s Association International Conference (AAIC)
July 31, 2024Research and Development Alzheimers, Conference results, Eisai, Neurology
Clarity AD open-label extension (OLE) data show: three years of continuous lecanemab treatment reduced clinical decline by -0.95 vs expected …
Eisai and Biogen’s Leqembi launched for Alzheimer’s treatment in China
June 28, 2024Business Services Alzheimers, Biogen, Eisai, Leqembi, Neurology, lecanemab
Eisai and Biogen have announced that Leqembi (lecanemab) has been launched in China as a treatment for mild cognitive impairment …
Axon seeks global partner after positive Phase 2 data for Alzheimer’s vaccine
September 10, 2019Manufacturing and Production, Sales and Marketing Alzheimer's, Alzheimers, Axon
Axon Neuroscience has announced data from its Phase 2 trial ADAMANT for the first-in-class vaccine AADvac1 to slow the progression …
FDA to crack down on dietary supplements
February 12, 2019Manufacturing and Production Alzheimer's, Alzheimers, Cancer, Dietary Supplements, FDA, USA, diabetes
The FDA is cracking down on those selling ‘dietary supplements’, having sent warning letters to companies who claim, without proof, …
Benzodiazepines increase stroke risk in Alzheimer’s patients, study finds
January 16, 2017Research and Development, Sales and Marketing Alzheimer's, Alzheimers, benzodiazepines
Benzodiazepines and similar drugs could increase the risk of strokes in Alzheimer’s patients by as much as 20% according to …
AstraZeneca and Eli Lilly to enter Phase III on Alzheimer’s clinical trials
April 8, 2016Medical Communications AZD3293, Alzheimer's, Alzheimers, AstraZeneca, amaranth, clinical trial, lilly, phase III
AstraZeneca and Eli Lilly have announced the continuation of their clinical trial for people with early Alzheimer’s disease into Phase …
Heptares announces positive early-stage dementia trial results
February 10, 2016Research and Development Alzheimer's, Alzheimers, Heptares, dementia, schizophrenia
Heptares has announced positive findings from its Phase 1b clinical study with its investigational drug HTL9936 as a treatment for …
Merck signs Alzheimer’s deal with Alectos
August 16, 2010Research and Development, Sales and Marketing Alzheimer's, Alzheimers, Merck & Co
Merck has entered a $289 million agreement with Canadian company Alectos Therapeutics in a bid to find new Alzheimer’s drugs. …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
